Fingerprint
Dive into the research topics of 'Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically